Dietary Supplements Commonly Used for Prevention

Primary Care - Clinics in Office Practice

Volumn 35, Issue 4, 2008, Pages 749-767

  Najm, Wadie ^a   Lie, Désirée ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Benefit; Complementary alternative medicine; Evidence; Harm; Herbals; Prevention

Indexed keywords

CELECOXIB; CHONDROITIN SULFATE; CIMICIFUGA RACEMOSA EXTRACT; CONJUGATED ESTROGEN; CRANBERRY EXTRACT; DOCOSAHEXAENOIC ACID; ECHINACEA EXTRACT; FISH OIL; GINGER EXTRACT; GINKGO BILOBA EXTRACT; GLUCOSAMINE; HERBACEOUS AGENT; ICOSAPENTAENOIC ACID; ISOFLAVONE; LINOLEIC ACID; LINSEED OIL; LYCOPENE; MANGANESE ASCORBATE; MANGANESE DERIVATIVE; PLACEBO; POLYPHENOL; PROANTHOCYANIDIN; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RESVERATROL; SILYBUM MARIANUM EXTRACT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEGETABLE OIL; WARFARIN; XANTHOPHYLL;

ABDOMINAL DISCOMFORT; AESCULUS HIPPOCASTANUM; ALLERGIC REACTION; ALOPECIA; ALTERNATIVE MEDICINE; ALZHEIMER DISEASE; ANTIFUNGAL ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; ARTHRITIS; ASTHMA; ATOPIC DERMATITIS; BERRY; BILBERRY; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CATARACT; CHRONIC DISEASE; CIMICIFUGA RACEMOSA; CLINICAL TRIAL; COMMON COLD; CONSTIPATION; CRANBERRY; CROHN DISEASE; DEMENTIA; DEPRESSION; DIARRHEA; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE EXACERBATION; DISORDERS OF CARBOHYDRATE METABOLISM; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ECHINACEA; ENZYME INHIBITION; EPIGASTRIC PAIN; ESCHERICHIA COLI; EXTRASYSTOLE; EYE DISEASE; EYELID EDEMA; FOOD AND DRUG ADMINISTRATION; GARLIC; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GINGER; GINSENG; GYNECOLOGIC DISEASE; HEADACHE; HEART ARRHYTHMIA; HEARTBURN; HELICOBACTER PYLORI; HEPATITIS; HERB; HERBAL MEDICINE; HUMAN; HYPERICUM PERFORATUM; HYPOTENSION; INTESTINE OBSTRUCTION; LEUKOPENIA; LINSEED; LIVER REGENERATION; MASTALGIA; MEDICINAL PLANT; MEMORY DISORDER; MENOPAUSAL SYNDROME; MUSCULOSKELETAL DISEASE; NAUSEA; NAUSEA AND VOMITING; NEOPLASM; NEPHROLITHIASIS; NEPHROTOXICITY; NEUROLOGIC DISEASE; NUT; NUTRITIONAL ASSESSMENT; OSTEOARTHRITIS; OXIDATIVE STRESS; PAIN; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RADIODIAGNOSIS; RASH; RED CLOVER; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK FACTOR; SABAL; SECONDARY PREVENTION; SEIZURE; SIDE EFFECT; SILYBUM MARIANUM; SKIN DISEASE; SKIN INFECTION; SOYBEAN; SWEATING; TEA; TRAVELLER DIARRHEA; TRIACYLGLYCEROL BLOOD LEVEL; ULCERATIVE COLITIS; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VAGINAL DRYNESS; VASOMOTOR REFLEX; VISUAL ACUITY; VOMITING; YOHIMBE;

CAMELLIA SINENSIS; CARDIOVASCULAR DISEASES; CAROTENOIDS; CHONDROITIN; CIMICIFUGA; DIETARY SUPPLEMENTS; ECHINACEA; FISH OILS; FLAX; GINGER; GLUCOSAMINE; HUMANS; INFLAMMATORY BOWEL DISEASES; LUTEIN; MILK THISTLE; NEOPLASMS; PLANT PREPARATIONS; PRIMARY HEALTH CARE; PRIMARY PREVENTION; PROBIOTICS; UNITED STATES; VACCINIUM MACROCARPON;

EID: 53349129570     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2008.07.010     Document Type: Review

References (129)

1. Gardiner P., Graham R., Legedza A.T., et al. Factors associated with herbal therapy use by adults in the United States. Altern Ther Health Med 13 2 (2007) 22-29
2. Brody J. Herbal and natural don't always mean safe. New York Times, February 4 (2003) D7
3. FDA. Dietary Supplement Health and Education Act of 1994 Public Law 103-417. Available at:. http://www.fda.gov/opacom/laws/dshea.html#sec3 Accessed September 11, 2008
4. Marinac J.S., Buchinger C.L., Godfrey L.A., et al. Herbal products and dietary supplements: a survey of use, attitudes, and knowledge among older adults. J Am Osteopath Assoc 107 1 (2007) 13-20
5. Eisenberg D. Advising patients who seek alternative medical therapies. Ann Intern Med 127 1 (1997) 61-69
6. Blumenthal M.F., Grant K.L., and Cavaliere C. Total sales of herbal supplements in United States show steady growth. HerbalGram 71 (2006) 64-66
7. American Botanical Council. Available at:. abc.herbalgram.org/site/PageServer Accessed March 26, 2008
8. Borrelli F., and Ernst E. Cimicifuga racemosa: a systematic review of its clinical efficacy. Eur J Clin Pharmacol 58 4 (2002) 235-241
9. Huntley A.L., and Ernst E. A systematic review of herbal medicinal products for the treatment of menopausal symptoms. Menopause 10 5 (2003) 465-476
10. Natural Standard Database. Available at:. www.naturalstandard.com/index.asp Accessed March 26, 2008 (by subscription only)
11. Osmers R., Friede M., Liske E., et al. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol 105 5 Pt 1 (2005) 1074-1083
12. Uebelhack R., Blohmer J.U., Graubaum H.J., et al. Black cohosh and St. John's wort for climacteric complaints: a randomized trial. Obstet Gynecol 107 2 Pt 1 (2006) 247-255
13. Wuttke W., Seidlová-Wuttke D., and Gorkow C. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas 44 Suppl 1 (2003) S67-S77
14. Newton K.M., Reed S.D., LaCroix A.Z., et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 145 12 (2006) 869-879
15. Newton K.M., Reed S.D., Grothaus L., et al. The Herbal Alternatives for Menopause (HALT) Study: background and study design. Maturitas 52 2 (2005) 134-146
16. Frei-Kleiner S., Schaffner W., Rahlfs V.W., et al. Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial. Maturitas 51 4 (2005) 397-404 [Epub 2004 Dec 10]
17. Verhoeven M.O., van der Mooren M.J., van de Weijer P.H., et al., CuraTrial Research Group. Effect of a combination of isoflavones and actaea racemosa linnaeus on climacteric symptoms in healthy symptomatic perimenopausal women: a 12-week randomized, placebo-controlled, double-blind study. Menopause 12 4 (2005) 412-420
18. Howell A.B., and Foxman B. Cranberry juice and adhesion of antibiotic-resistant uropathogens. JAMA 287 23 (2002) 3082-3083
19. Jepson R.G., and Craig J.C. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev Issue 1 (2008) Art. No.: CD001321. 10.1002/14651858.CD001321.pub4
20. Kontiokari T., Sundqvist K., Nuutinen M., et al. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ 322 7302 (2001) 1571-1573
21. Elliott S.P., Villar R., and Duncan B. Bacteriuria management and urological evaluation of patients with spina bifida and neurogenic bladder: a multicenter survey. J Urol 173 1 (2005) 217-220
22. Kontiokari T., Salo J., Eerola E., et al. Cranberry juice and bacterial colonization in children-a placebo-controlled randomized trial. Clin Nutr 24 6 (2005) 1065-1072
23. Waites K.B., Canupp K.C., Armstrong S., et al. Effect of cranberry extract on bacteriuria and pyuria in persons with neurogenic bladder secondary to spinal cord injury. J Spinal Cord Med 27 1 (2004) 35-40
24. Linsenmeyer T.A., Harrison B., Oakley A., et al. Evaluation of cranberry supplement for reduction of urinary tract infections in individuals with neurogenic bladders secondary to spinal cord injury. A prospective, double-blinded, placebo-controlled, crossover study. J Spinal Cord Med 27 1 (2004) 29-34
25. McMurdo M.E., Bissett L.Y., Price R.J., et al. Does ingestion of cranberry juice reduce symptomatic urinary tract infections in older people in hospital? A double-blind, placebo-controlled trial. Age Ageing 34 3 (2005) 256-261
26. Jepson R.G., Mihaljevic L., and Craig J.C. Cranberries for treating urinary tract infections. Cochrane Database Syst Rev Issue 4 (1998) Art. No: CD001322
27. McHarg T., Rodgers A., and Charlton K. Influence of cranberry juice on the urinary risk factors for calcium oxalate kidney stone formation. BJU Int 92 7 (2003) 765-768
28. Gilroy C.M., Steiner J.F., Byers T., et al. Echinacea and truth in labeling. Arch Intern Med 163 6 (2003) 699-704
29. Turner R.B., Bauer R., Woelkart K., et al. An evaluation of echinacea angustifolia in experimental rhinovirus infections. N Engl J Med 353 4 (2005) 341-348
30. Taylor J.A., Weber W., Standish L., et al. Efficacy and safety of echinacea in treating upper respiratory tract infections in children: a randomized-controlled trial. JAMA 290 21 (2003) 2824-2830
31. Barrett B.P., Brown R.L., Locken K., et al. Treatment of the common cold with unrefined echinacea. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137 12 (2002) 939-946
32. Dorn M., Knick E., and Lewith G. Placebo-controlled, double-blind study of echinaceae pallidae radix in upper respiratory tract infections. Complement Ther Med 5 (1997) 40-42
33. Bräunig B., Dorn M., Limburg E., et al. Enhancement of resistance in common cold by echinacea purpurea radix. Zeitschrift fur Phytotherpie 13 1 (1992) 7-13
34. Melchart D., Linde K., Fischer P., et al. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev 2 (2000) CD000530
35. Yokoyama M., Origasa H., Matsuzaki M., et al., Japan EPA Lipid Intervention Study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369 9567 (2007) 1090-1098
36. Hooper L., Thompson R.L., Harrison R.A., et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev Issue 4 (2004) Art. No: CD003177
37. Hu F.B., Bronner L., Willett W.C., et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 287 14 (2002) 1815-1821
38. MacLean C.H., Newberry S.J., Mojica W.A., et al. Effects of omega-3 fatty acids on cancer risk: a systematic review. JAMA 295 4 (2006) 403-415
39. Issa A.M., Mojica W.A., Morton S.C., et al. The efficacy of omega-3 fatty acids on cognitive function in aging and dementia: a systematic review. Dement Geriatr Cogn Disord 21 2 (2006) 88-96
40. Lim W.S., Gammack J.K., Van Niekerk J., et al. Omega 3 fatty acid for the prevention of dementia. Cochrane Database Syst Rev 1 (2006) CD005379
41. Maclean C.H., Issa A.M., Newberry S.J., et al. Effects of omega-3 fatty acids on cognitive function with aging, dementia, and neurological diseases. Evid Rep Technol Assess (Summ) 114 (2005) 1-3
42. Feagan B.G., Sandborn W.J., Mittmann U., et al. Omega-3 free fatty acids for the maintenance of remission in Crohn's disease: the EPIC randomized controlled trials. JAMA 299 (2008) 1690-1697
43. Sommerfield T., Price J., and Hiatt W.R. Omega-3 fatty acids for intermittent claudication. Cochrane Database Syst Rev Issue 4 (2007) Art. No.: CD003833
44. Ridges L., Sunderland R., Moerman K., et al. Cholesterol-lowering benefits of soy and linseed enriched foods. Asia Pac J Clin Nutr 10 3 (2001) 204-211
45. Lemay A., Dodin S., Kadri N., et al. Flaxseed dietary supplement versus hormone replacement therapy in hypercholesterolemic menopausal women. Obstet Gynecol 100 3 (2002) 495-504
46. Mandasescu S., Mocanu V., Dǎscaliţa A.M., et al. Flaxseed supplementation in hyperlipidemic patients. Rev Med Chir Soc Med Nat Iasi 109 3 (2005) 502-506
47. Tarpila S., and Kivinen A. Ground flaxseed is an effective hypolipidemic bulk laxative. Gastroenterology 112 (1997) A836
48. Dahl W.J., Lockert E.A., Cammer A.L., et al. Effects of flax fiber on laxative and glycemic response in healthy volunteers. J Med Food 8 4 (2005) 508-511
49. Cunnane S.C., Hamadeh M.J., Liede A.C., et al. Nutritional attributes of traditional flaxseed in healthy young adults. Am J Clin Nutr 61 1 (1995) 62-68
50. Goss P.E., Li T., Theriault M., et al. Effects of dietary flaxseed in women with cyclical mastalgia. Breast Cancer Res Treat 64 1 (2000) 49
51. Lewis J.E., Nickell L.A., Thompson L.U., et al. A randomized-controlled trial of the effect of dietary soy and flaxseed muffins on quality of life and hot flashes during menopause. Menopause 13 4 (2006) 631-642
52. Basch E., Bent S., Collins J., et al., Natural Standard Resource Collaboration. Flax and flaxseed oil (linum usitatissimum): a review by the Natural Standard Research Collaboration. J Soc Integr Oncol 5 3 (2007) 92-105
53. Micklefield G.H., Redeker Y., Meister V., et al. Effects of ginger on gastroduodenal motility. Int J Clin Pharmacol Ther 37 7 (1999) 341-346
54. Lumb A.B. Mechanism of antiemetic effect of ginger. Anaesthesia 48 12 (1993) 1118
55. Chaiyakunapruk N., Kitikannakorn P., Nathisuwan S., et al. The efficacy of ginger for the prevention of postoperative nausea and vomiting: a meta-analysis. Am J Obstet Gynecol 194 1 (2006) 95-99
56. Betz O., Kranke P., Geldner G., et al. Is ginger a clinically relevant antiemetic? A systematic review of randomized-controlled trials. Forsch Komplementarmed Klass Naturheilkd 12 1 (2005) 14-23
57. Lumb A.B. Effect of dried ginger on human platelet function. Thromb Haemost 71 1 (1994) 110-111
58. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. Available at:. www.nap.edu/books/0309072794/html/
59. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. Available at: (2002), National Academy Press, Washington, DC Accessed August 30, 2007
60. Towheed T.E., Maxwell L., Anastassiades T.P., et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2 (2005) CD002946
61. Pavelka K., Gatterova J., Olejarova M., et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 162 (2002) 2113-2123
62. Clegg D.O., Reda D.J., Harris C.L., et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 354 (2006) 795-808
63. Rother M., Lavins J., Kneer W., et al. Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised-controlled trial and placebo in osteoarthritis of the knee. Ann Rheum Dis 66 (2007) 1178-1183 [originally published online 15 Mar 2007]
64. Cohen M., Wolfe R., Mai T., et al. A randomized, double-blind, placebo-controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. J Rheumatol 30 (2003) 523-528
65. Pham T., Cornea A., Blick K.E., et al. Oral glucosamine in doses used to treat osteoarthritis worsens insulin resistance. Am J Med Sci 333 (2007) 333-339
66. Scroggie D.A., Albright A., and Harris M.D. The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial. Arch Intern Med 163 (2003) 1587-1590
67. Muniyappa R., Karne R.J., Hall G., et al. Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects. Diabetes 55 (2006) 3142-3150
68. Tannis A.J., Barban J., and Conquer J.A. Effect of glucosamine supplementation on fasting and nonfasting plasma glucose and serum insulin concentrations in healthy individuals. Osteoarthritis Cartilage 12 (2004) 506-511
69. Chen L., and Zhang H.Y. Cancer preventive mechanisms of the green tea polyphenol (-)-epigallocatechin-3-gallate. Molecules 12 5 (2007) 946-957
70. Syed D.N., Afaq F., Kweon M.H., et al. Green tea polyphenol EGCG suppresses cigarette smoke condensate-induced NF-kappaB activation in normal human bronchial epithelial cells. Oncogene 26 5 (2007) 673-682
71. Wang L.D., Zhou Q., Feng C.W., et al. Intervention and follow-up on human esophageal precancerous lesions in Henan, northern China, a high-incidence area for esophageal cancer. Gan To Kagaku Ryoho 29 Suppl 1 (2002) 159-172
72. Gao Y.T., McLaughlin J.K., Blot W.J., et al. Reduced risk of esophageal cancer associated with green tea consumption. J Natl Cancer Inst 86 11 (1994) 855-858
73. Tsubono Y., Nishino Y., Komatsu S., et al. Green tea and the risk of gastric cancer in Japan. N Engl J Med 344 9 (2001) 632-636
74. Nagano J., Kono S., Preston D.L., et al. A prospective study of green tea consumption and cancer incidence, Hiroshima and Nagasaki (Japan). Cancer Causes Control 12 6 (2001) 501-508
75. Ji B.T., Chow W.H., Hsing A.W., et al. Green tea consumption and the risk of pancreatic and colorectal cancers. Int J Cancer 70 3 (1997) 255-258
76. Tipoe G.L., Leung T.M., Hung M.W., et al. Green tea polyphenols as an antioxidant and anti-inflammatory agent for cardiovascular protection. Cardiovasc Hematol Disord Drug Targets 7 2 (2007) 135-144
77. Basu A., and Lucas E.A. Mechanisms and effects of green tea on cardiovascular health. Nutr Rev 65 8 Pt 1 (2007) 361-375
78. Sommerburg O., Keunen J.E., Bird A.C., et al. Fruits and vegetables that are sources for lutein and zeaxanthin: the macular pigment in human eyes. Br J Ophthalmol 82 8 (1998) 907-910
79. Seddon J.M., Ajani U.A., Sperduto R.D., et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA 272 18 (1994) 1413-1420 [erratum in: JAMA. 1995 Feb 22;273(8):622]
80. Goldberg J., Flowerdew G., Smith E., et al. Factors associated with age-related macular degeneration. An analysis of data from the first National Health and Nutrition Examination Survey. Am J Epidemiol 128 4 (1988) 700-710
81. Cho E., Seddon J.M., Rosner B., et al. Prospective study of intake of fruits, vegetables, vitamins, and carotenoids and risk of age-related maculopathy. Arch Ophthalmol 122 6 (2004) 883-892
82. Richer S., Stiles W., Statkute L., et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry 75 4 (2004) 216-230
83. Richer S., Devenport J., and Lang J.C. LAST II: differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry 78 5 (2007) 213-219
84. Chasan-Taber L., Willett W.C., Seddon J.M., et al. A prospective study of carotenoid and vitamin A intakes and risk of cataract extraction in US women. Am J Clin Nutr 70 4 (1999) 509-516
85. Brown L., Rimm E.B., Seddon J.M., et al. A prospective study of carotenoid intake and risk of cataract extraction in US men. Am J Clin Nutr 70 4 (1999) 517-524
86. Olmedilla B., Granado F., Blanco I., et al. Lutein, but not alpha-tocopherol, supplementation improves visual function in patients with age-related cataracts: a 2-y double-blind, placebo-controlled pilot study. Nutrition 19 1 (2003) 21-24
87. Arab L., and Steck S. Lycopene and cardiovascular disease. Am J Clin Nutr 71 Suppl 6 (2000) S1691-S1695
88. Giovannucci E. A review of epidemiologic studies of tomatoes, lycopene, and prostate cancer. Exp Biol Med (Maywood) 227 10 (2002) 852-859
89. Kucuk O., Sarkar F.H., Djuric Z., et al. Effects of lycopene supplementation in patients with localized prostate cancer. Exp Biol Med (Maywood) 227 10 (2002) 881-885
90. Kirsh V.A., Mayne S.T., Peters U., Chatterjee N., et al. A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15 1 (2006) 92-98
91. Kirsh V.A., Peters U., Mayne S.T., et al. Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Prospective study of fruit and vegetable intake and risk of prostate cancer. J Natl Cancer Inst 99 15 (2007) 1200-1209
92. Schwarz S., Obermüller-Jevic U.C., Hellmis E., et al. Lycopene inhibits disease progression in patients with benign prostate hyperplasia. J Nutr 138 1 (2008) 49-53
93. Hikino H., Kiso Y., Wagner H., et al. Antihepatotoxic actions of flavonolignans from silybum marianum fruits. Planta Med 50 3 (1984) 248-250
94. Gonzalez-Correa J.A., de la Cruz J.P., Gordillo J., et al. Effects of silymarin MZ-80 on hepatic oxidative stress in rats with biliary obstruction. Pharmacology 64 1 (2002) 18-27
95. Maitrejean M., Comte G., Barron D., et al. The flavanolignan silybin and its hemisynthetic derivatives, a novel series of potential modulators of P-glycoprotein. Bioorg Med Chem Lett 10 2 (2000) 157-160
96. Dehmlow C., Murawski N., and deGroot H. Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silybinin in human cells. Life Sci 58 (1996) 1591-1600
97. Sonnenbichler J., Goldberg M., Hane L., et al. Stimulatory effect of silibinin on the DNA synthesis in partially hepatectomized rat livers: nonresponse in hepatoma and other malign cell lines. Biochem Pharmacol 35 3 (1986) 538-541
98. Sonnenbichler J., Scalera F., Sonnenbichler I., et al. Stimulatory effects of silibinin and silicristin from the milk thistle silybum marianum on kidney cells. J Pharmacol Exp Ther 290 3 (1999) 1375-1383
99. Jacobs B.P., Dennehy C., Ramirez G., et al. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am J Med 113 6 (2002) 506-515
100. Lawrence V, Jacobs B, Dennehy C, et al. Milk thistle: effects on liver disease and cirrhosis and clinical adverse effects. Summary. Evidence report/technology assessment: number 21. Rockville, MD: (Contract 290-97-0012 to the San Antonio Evidence-based Practice Center, based at the University of Texas Health Science Center at San Antonio, and The Veterans Evidence-based Research, Dissemination, and Implementation Center, a Veterans Affairs Services Research and Development Center of Excellence). October 2000
101. Magula D., Galisova Z., Iliev N., et al. Effect of silymarin and fumaria alkaloids in the prophylaxis of drug-induced liver injury during antituberculotic treatment. Studia Pneumologica Phtiseologica et Cechoslov 56 5 (1996) 206-209
102. Chlopcíková S., Psotova J., Miketová P., et al. Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part I. Silymarin and its flavonolignans. Phytother Res 18 2 (2004) 107-110
103. Beckmann-Knopp S., Rietbrock S., Weyhenmeyer R., et al. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol 86 6 (2000) 250-256
104. McFarland L.V. Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med infect Dis 5 (2007) 97-105
105. Johnston B.C., Supina A.L., and Vohra S. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. Can Med Assoc J 175 (2006) 377-383
106. D'Souza A.L., Rajkumar C., Cooke J., et al. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 324 (2002) 1361-1367
107. McFarland L. Meta-analysis of probiotics for the prevention of antibiotic-associated diarrhea and the treatment of clostridium difficile disease. Am J Gastroenterol 101 4 (2006) 812-822
108. Hickson M., D'Souza A.L., Muthu N., et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomized, double-blind, placebo-controlled trial. BMJ 335 7610 (2007) 80-85
109. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind placebo-controlled trial 3. 2003;124:1202-1209.
110. Mimura T., Rizzello F., Helwig U., et al. Once-daily high dose of probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. GUT 53 (2004) 108-114
111. Zocco M.A., dal Verme L.Z., Cermonini F., et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 23 (2006) 1567-1574
112. Guslandi M., Mezzi G., Sorghi M., et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 45 7 (2000) 1462-1464
113. Rolfe V.E., Fortun P.J., Hawkey C.J., et al. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 4 (2006) CD004826
114. Osborn D.A., and Sinn J.K. Probiotics in infants for prevention of allergic disease and food hypersensitivity. Cochrane Database Syst Rev 4 (2007) CD006475
115. Osborn D.A., and Sinn J.K. Prebiotics in infants for prevention of allergic disease and food hypersensitivity. Cochrane Database Syst Rev 4 (2007) CD006474
116. McNabb B., and Isakow W. Probiotics for the prevention of nosocomial pneumonia: current evidence and opinions. Curr Opin Pulm Med 14 3 (2008) 168-175
117. Shankar S., Singh G., and Srivastava R.K. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front Biosci 12 (2007) 4839-4854
118. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., et al. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24 5A (2004) 2783-2840
119. Lin J.K., and Tsai S.H. Chemoprevention of cancer and cardiovascular disease by resveratrol. Proc Natl Sci Counc Repub China B 23 3 (1999) 99-106
120. Delmas D., Lancon A., Colin D., et al. Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr Drug Targets 7 4 (2006) 423-442
121. Sato M., Ray P.S., Maulik G., et al. Myocardial protection with red wine extract. J Cardiovasc Pharmacol 35 2 (2000) 263-268
122. Ray P.S., Maulik G., Cordis G.A., et al. The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radic Biol Med 27 1-2 (1999) 160-169
123. Dernek S., Ikizler M., Erkasap N., et al. Cardioprotection with resveratrol pretreatment: improved beneficial effects over standard treatment in rat hearts after global ischemia. Scand Cardiovasc J 38 4 (2004) 245-254
124. Athar M., Back J.H., Tang X., et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 224 3 (2007) 274-283
125. Wang Z., Huang Y., Zou J., et al. Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int J Mol Med 9 1 (2002) 77-79
126. Zbikowska H.M., and Olas B. Antioxidants with carcinostatic activity (resveratrol, vitamin E, and selenium) in modulation of blood platelet adhesion. J Physiol Pharmacol 51 3 (2000) 513-520
127. Surh Y.J., Chun K.S., Cha H.H., et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res 480-481 (2001) 243-268
128. Csiszar A., Smith K., Labinskyy N., et al. Resveratrol attenuates TNF-alpha-induced activation of coronary arterial endothelial cells: role of NF-kappaB inhibition. Am J Physiol Heart Circ Physiol 1 4 (2006) H1694-H1699
129. MacLean C.H., Mojica W.A., Newberry S.J., et al. Systematic review of the effects of n-3 fatty acids in inflammatory bowel disease. Am J Clin Nutr 82 3 (2005) 611-619